Fundraising FoxBioAdvance — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Eliksa Therapeutics develops innovative treatments for rare diseases with unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsMilitia Hill VenturesBen Franklin Technology Partners
BiotechNew York, US
Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)
BoardJonathan Leff(Director)David Greenwald(Director)in
Co-investorsDeerfield Management Company
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
BiotechMalvern, US
Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)
Co-investorsAMR Action FundForesite CapitalVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Senzo
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.